Recently, a pooled analysis of 2310 patients with HER2 non-amplified early BC from four prospective neoadjuvant clinical trials, published by Denkert etal., included 1162 patients with TNBC (395 patients HER2-low and 767 HER2-0). This evidence concerns the gene ERBB2 and breast cancer.